AR016877A2 - 6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales - Google Patents

6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales

Info

Publication number
AR016877A2
AR016877A2 ARP980104218A ARP980104218A AR016877A2 AR 016877 A2 AR016877 A2 AR 016877A2 AR P980104218 A ARP980104218 A AR P980104218A AR P980104218 A ARP980104218 A AR P980104218A AR 016877 A2 AR016877 A2 AR 016877A2
Authority
AR
Argentina
Prior art keywords
tert
substituted
diseases
methanol
compounds
Prior art date
Application number
ARP980104218A
Other languages
English (en)
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of AR016877A2 publication Critical patent/AR016877A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se refiere a 6-ter-butiloxicarbonilaminopiridinas 2 sustituidas por grupos metanol o metilo y sus sales de metanosulfonato, cloruro o bromuro. Enparticular se refiere a 6-terbutiloxicarbonilaminopiridina-2-metanol, metansulfonato de 6-ter-butiloxicarbonilaminopiridin-2-il-metilo, cloruro de 6-ter-butiloxicarbonil aminopiridin-2-ilmetilo y bromuro de 6-ter-butiloxicarbonilamino-piridin-2-ilmetilo. Los compuestos de la invencion son utiles comoreactivos para preparar derivados de piperidina 1,4-disustituida que contienen fluor. Los derivados preparados a partir de los compuestos de la invenciontienen no solo un antagonismo potente y selectivo para los receptores M3 muscarínicos sino también tienen pocos efectos colaterales. Más aun, exhibenuna excelente actividad oral, duracion de accion y farmacocinética. Por lo tanto son utiles para el tratamiento profilaxis de las enfermedades respiratorias,las enfermedades urinarias y las enfermedades digestivas.
ARP980104218A 1996-08-01 1998-08-25 6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales AR016877A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21943696 1996-08-01
JP5397997 1997-02-21

Publications (1)

Publication Number Publication Date
AR016877A2 true AR016877A2 (es) 2001-08-01

Family

ID=26394715

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP970103516A AR008272A1 (es) 1996-08-01 1997-08-01 Derivados de piperidina 1,4-disustituida que contienen fluor, composicion farmaceutica compuesta de los mismos y un proceso para su preparacion
ARP980104219A AR017021A1 (es) 1996-08-01 1998-08-25 Acido 2-hidroxiacetico
ARP980104218A AR016877A2 (es) 1996-08-01 1998-08-25 6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP970103516A AR008272A1 (es) 1996-08-01 1997-08-01 Derivados de piperidina 1,4-disustituida que contienen fluor, composicion farmaceutica compuesta de los mismos y un proceso para su preparacion
ARP980104219A AR017021A1 (es) 1996-08-01 1998-08-25 Acido 2-hidroxiacetico

Country Status (29)

Country Link
US (2) US5948792A (es)
EP (1) EP0930298B1 (es)
JP (1) JP3063164B2 (es)
KR (1) KR20000022214A (es)
CN (1) CN1226888A (es)
AR (3) AR008272A1 (es)
AT (1) ATE229941T1 (es)
AU (1) AU716050B2 (es)
BG (1) BG103114A (es)
BR (1) BR9711108A (es)
CA (1) CA2261680C (es)
CO (1) CO4960641A1 (es)
CZ (1) CZ33199A3 (es)
DE (1) DE69718026T2 (es)
EE (1) EE9900038A (es)
ES (1) ES2188961T3 (es)
HR (1) HRP970426A2 (es)
HU (1) HUP9902381A3 (es)
ID (1) ID17259A (es)
IL (1) IL127685A0 (es)
IS (1) IS4960A (es)
NO (1) NO990472D0 (es)
NZ (1) NZ333842A (es)
PE (1) PE92198A1 (es)
PL (1) PL331431A1 (es)
SK (1) SK12299A3 (es)
TR (2) TR199900204T2 (es)
WO (1) WO1998005641A1 (es)
YU (1) YU1299A (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180823B1 (en) 1998-11-06 2001-01-30 Sepracor Inc. Stereoselective process for alkyl phenylglycolic acids
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
WO2000061572A1 (en) * 1999-04-08 2000-10-19 Merck & Co., Inc. Diastereoselective preparation of michael adducts
WO2000066579A1 (en) * 1999-04-28 2000-11-09 Banyu Pharmaceutical Co., Ltd. Processes for the preparation of piperidylmethylpyridine derivatives
WO2001013918A1 (en) * 1999-08-23 2001-03-01 H. Lundbeck A/S Treatment of urinary incontinence
MXPA02005596A (es) * 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
EP1242083B1 (fr) * 1999-12-17 2007-03-14 Sanofi-Aventis Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6469172B2 (en) 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
CN1250545C (zh) 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
EP1438035A2 (en) * 2001-09-27 2004-07-21 Pharmacia AB Pharmaceutical compositions for the treatment of urinary disorders
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
NZ537584A (en) 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US6583103B1 (en) 2002-08-09 2003-06-24 S.C. Johnson & Son, Inc. Two part cleaning formula resulting in an effervescent liquid
AU2002321711A1 (en) 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有3,6−二置換アザビシクロ(3.1.0)ヘキサン誘導体
JP2006506392A (ja) * 2002-10-29 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ムスカリン受容体アンタゴニストとしての第四級アンモニウム化合物
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
AU2002347552A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) * 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2521788A1 (en) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
JP2007524641A (ja) 2003-07-11 2007-08-30 セラヴァンス, インコーポレーテッド 置換4−アミノ−1−ベンジルピペリジン化合物
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
US7728025B2 (en) * 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
EP1765809B1 (en) * 2004-06-16 2008-12-31 Ranbaxy Laboratories Limited Xanthine derivatives useful as muscarinic receptor antagonists
EP1781607A2 (en) * 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
WO2006032994A2 (en) * 2004-09-24 2006-03-30 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
AU2005301608B2 (en) 2004-11-02 2012-09-13 Msd K.K. Aryloxy-substituted benzimidazole derivatives
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
CA2623958C (en) * 2005-09-30 2013-05-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
WO2007039884A1 (en) * 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
JP5656288B2 (ja) 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
ES2511844T3 (es) * 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 1−(1,3−ジオキソラン−4−イルメチル)ピペリジノ−ル誘導体
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP0823423B1 (en) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
DE69615214T2 (de) * 1995-10-13 2002-06-27 Banyu Pharmaceutical Co., Ltd. Substituierte heteroaromatische derivate

Also Published As

Publication number Publication date
US6040449A (en) 2000-03-21
IS4960A (is) 1999-01-29
US5948792A (en) 1999-09-07
EE9900038A (et) 1999-08-16
ATE229941T1 (de) 2003-01-15
PL331431A1 (en) 1999-07-19
WO1998005641A1 (en) 1998-02-12
AR008272A1 (es) 1999-12-29
EP0930298B1 (en) 2002-12-18
KR20000022214A (ko) 2000-04-25
ID17259A (id) 1997-12-11
CO4960641A1 (es) 2000-09-25
ES2188961T3 (es) 2003-07-01
CZ33199A3 (cs) 1999-07-14
AR017021A1 (es) 2001-08-22
HUP9902381A2 (hu) 1999-11-29
NZ333842A (en) 2001-05-25
CN1226888A (zh) 1999-08-25
TR199900204T2 (xx) 2000-01-21
AU3635197A (en) 1998-02-25
NO990472L (no) 1999-02-01
YU1299A (sh) 2002-03-18
DE69718026D1 (de) 2003-01-30
HRP970426A2 (en) 1998-08-31
IL127685A0 (en) 1999-10-28
HUP9902381A3 (en) 2000-06-28
DE69718026T2 (de) 2003-07-10
TR200001482T2 (tr) 2000-11-21
AU716050B2 (en) 2000-02-17
BR9711108A (pt) 1999-08-17
CA2261680C (en) 2005-03-08
BG103114A (en) 1999-11-30
EP0930298A4 (en) 2000-06-07
SK12299A3 (en) 2000-05-16
PE92198A1 (es) 1999-01-09
JP3063164B2 (ja) 2000-07-12
EP0930298A1 (en) 1999-07-21
CA2261680A1 (en) 1998-02-12
NO990472D0 (no) 1999-02-01

Similar Documents

Publication Publication Date Title
AR017021A1 (es) Acido 2-hidroxiacetico
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
UY26872A1 (es) Derivados de la 4- fenil piridina
CY1106276T1 (el) Παραγωγα υποκατεστημενου φαινυλπροπιονικου οξεος ως ανταγωνιστες σε υποδοχεις αλφα που ενepγοποιουνται απο παραγοντες που επαγουν τον πολλαπλασιασμο των ανθρωπινων υπepοξεισωματων (ppar)
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
CO5570667A2 (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
SV2002000232A (es) Derivados nuevos de benzoimidazole utiles como agentes antiproliferativos ref. pc 10608abcz/bb
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
MX9707453A (es) Derivados de quinazolina.
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
UY27918A1 (es) Derivados de benzodioxol
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
EA200001061A1 (ru) Фармацевтическая композиция
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.